Mashup Score:13
OncLiveFDA Approves Olaparib/Abiraterone Combo for BRCA+ Metastatic Castration-Resistant Prostate Cancer - 1 week
Mashup Score:13
Mashup Score:13
OncLiveFDA Approves Olaparib/Abiraterone Combo for BRCA+ Metastatic Castration-Resistant Prostate Cancer - 1 week
Mashup Score:13
Mashup Score:13
OncLiveImetelstat Prolongs Transfusion Independence, Increases Hemoglobin in R/R MDS - 4 days
Mashup Score:13
Treatment with the first-in-class direct and competitive telomerase inhibitor imetelstat resulted in statistically significant and clinically meaningful efficacy in patients with heavily transfusion dependent,...
Imetelstat resulted in statistically significant efficacy in heavily transfusion dependent, non-del(5q) lower-risk R/R MDS to erythropoiesis stimulating agents. @Dr_AmerZeidan @YaleCancer @ASCO #ASCO2023 #mdssm #oncology https://t.co/ou3DcswkJQ - view on twitter
Mashup Score:12
ascopost.comDe Novo Metastatic Hormone-Sensitive Prostate Cancer – The ASCO Post - 7 days
Mashup Score:12
Transcript Disclaimer: This video transcript has not been proofread or edited and may contain errors. Dr. Alicia Morgans: Hi, and welcome to The ASCO...
RT @ASCOPost: Treating Locally Advanced High-Risk Prostate Cancer https://t.co/rEh9U6XtuU #pcsm #prostatecancer @CaPsurvivorship @DanaFarbe… - view on twitter
Treating Locally Advanced High-Risk Prostate Cancer https://t.co/rEh9U6XtuU #pcsm #prostatecancer @CaPsurvivorship @DanaFarber @neerajaiims @HuntsmanCancer @vanderweelemd @NUFeinbergMed #oncology - view on twitter
Mashup Score:12
OncLivePembrolizumab plus chemotherapy with or without bevacizumab led to a substantial improvement in overall survival vs placebo plus chemotherapy with or without bevacizumab in...
Pembro + chemotherapy w/ or w/o bevacizumab led to a substantial improvement in overall survival vs placebo plus chemotherapy with or without bevacizumab in pts with persistent, recurrent, or metastatic cervical cancer. @ASCO #ASCO2023 #gyncsm #oncology https://t.co/vk6pcZxV1O https://t.co/vk6pcZxV1O - view on twitter
Mashup Score:10
ascopost.comBy The ASCO Post Staff Posted: 6/3/2023 10:26:00 AM Last Updated: 6/3/2023 9:45:31 AM Patients with newly diagnosed advanced ovarian cancer without a BRCA...
Addition of Olaparib and Durvalumab to Standard of Care May Prolong Progression-Free Survival in Patients With Advanced Ovarian Cancer https://t.co/RYSwR8yQST #gyncsm #ovariancancer #ASCO23 #oncology - view on twitter
Mashup Score:9
OncLiveNALIRIFOX Elicits Statistically Significant Improvement in OS/PFS in Previously Untreated mPDAC - 5 days
Mashup Score:9
Liposomal irinotecan plus 5-fluorouracil/leucovorin and oxaliplatin generated statistically significant and clinically meaningful overall survival and progression-free survival benefits compared with gemcitabine plus nab-paclitaxel in...
NALIRIFOX Elicits Statistically Significant Improvement in OS/PFS in Previously Untreated mPDAC @MSKCancerCenter @ASCO #ASCO23 #ASCO2023 #oncology https://t.co/z6c6oUfScY - view on twitter
Mashup Score:8
Oncology Nursing NewsMirvetuximab soravtansine demonstrated an overall survival benefit in FRα-high, platinum-resistant ovarian cancer vs investigator’s choice...
Mirvetuximab soravtansine elicits practice-changing outcomes in Frα+ platinum-resistant ovarian cancer #ASCO23 #gyncsm #oncology #nursing @ASCO @StephensonCC https://t.co/U9z7IoSYKE - view on twitter
Mashup Score:8
ascopost.com2023 ASCO Annual Meeting Lisa A. Carey, MD, of the University of North Carolina at Chapel Hill, and Dennis J. Slamon, MD, PhD, of...
Lisa A. Carey, MD, and Dennis J. Slamon, MD, PhD, on Early Breast Cancer: Findings From the NATALEE Trial on Ribociclib Plus Endocrine Therapy https://t.co/x9z6xTK0fm #bcsm #breastcancer #oncology #ASCO23 @DrLisaCarey @UNC_Lineberger @UCLAHealth - view on twitter
Mashup Score:7
OncLiveGastrointestinal oncology experts discuss current strategies and novel developments in gastrointestinal cancers, the role of intestinal dysbiosis and gastrointestinal carcinogenesis, germline genetic features in...
Gastrointestinal oncology experts discuss current strategies and novel developments in GI cancers, the role of intestinal dysbiosis and GI carcinogenesis, germline genetic features in appendiceal cancer, and more. #oncology @CathyEngMD @VUMC_Cancer https://t.co/WBH8UiAyn7 - view on twitter
Mashup Score:7
ascopost.comEnrique Grande on Metastatic Urothelial Carcinoma Updated Data From IMvigor130 – The ASCO Post - 6 hours
Mashup Score:7
2023 ASCO Annual Meeting Enrique Grande, MD, of The University of Texas MD Anderson Cancer Center, discusses new findings that show initial responses to...
Enrique Grande, MD, on Metastatic Urothelial Carcinoma: Updated Data From IMvigor130 https://t.co/f21OkQIsJL #blcsm #bladdercancer #immunotherapy #oncology @drenriquegrande - view on twitter
The FDA has approved olaparib (Lynparza) plus abiraterone acetate (Zytiga) and prednisone or prednisolone for the treatment of patients with deleterious or suspected deleterious...
BREAKING: @US_FDA Approves Olaparib/Abiraterone Combo for BRCA+ Metastatic Castration-Resistant Prostate Cancer #pcsm #oncology https://t.co/zHMCyz3ExU https://t.co/zHMCyz3ExU - view on twitter